Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Expression of nerve growth factor and heme oxygenase-1 predict poor survival of breast carcinoma patients.

Noh SJ, Bae JS, Jamiyandorj U, Park HS, Kwon KS, Jung SH, Youn HJ, Lee H, Park BH, Chung MJ, Moon WS, Kang MJ, Jang KY.

BMC Cancer. 2013 Nov 1;13:516. doi: 10.1186/1471-2407-13-516.

2.

Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma.

Yang XQ, Xu YF, Guo S, Liu Y, Ning SL, Lu XF, Yang H, Chen YX.

World J Gastroenterol. 2014 Apr 14;20(14):4076-84. doi: 10.3748/wjg.v20.i14.4076.

3.

Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.

Davidson B, Reich R, Lazarovici P, Ann Flørenes V, Nielsen S, Nesland JM.

Breast Cancer Res Treat. 2004 Jan;83(2):119-28.

PMID:
14997042
4.

Combined evaluation of NGF and p75NGFR expression is a biomarker for predicting prognosis in human invasive ductal breast carcinoma.

Sakamoto Y, Kitajima Y, Edakuni G, Hamamoto T, Miyazaki K.

Oncol Rep. 2001 Sep-Oct;8(5):973-80.

PMID:
11496301
5.

High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.

Xu C, Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Murakami K, Okumura Y, Yamaguchi L, Fujiki Y, Iwase H.

Breast Cancer. 2014 Jul;21(4):482-90. doi: 10.1007/s12282-012-0403-9. Epub 2012 Sep 12.

PMID:
22968628
6.

Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.

Seong MK, Lee JY, Byeon J, Sohn YJ, Seol H, Lee JK, Kim EK, Kim HA, Noh WC.

Breast Cancer Res Treat. 2015 Feb;150(1):141-8. doi: 10.1007/s10549-015-3305-7. Epub 2015 Feb 15.

PMID:
25682076
7.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

8.

Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma.

Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, Koh DH, Moon WS, Jang KY.

Hum Pathol. 2011 Feb;42(2):204-13. doi: 10.1016/j.humpath.2010.05.023. Epub 2010 Nov 5.

PMID:
21056897
9.

Nerve growth factor is a potential therapeutic target in breast cancer.

Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R, Nurcombe V, Le Bourhis X, Hondermarck H.

Cancer Res. 2008 Jan 15;68(2):346-51. doi: 10.1158/0008-5472.CAN-07-1183.

10.

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.

Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G.

J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87.

PMID:
1281237
11.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

PMID:
23749689
12.

Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer.

Zhang Y, Dang C, Ma Q, Shimahara Y.

Oncol Rep. 2005 Jul;14(1):161-71.

PMID:
15944784
13.

Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer.

Cao YW, Li WQ, Wan GX, Li YX, Du XM, Li YC, Li F.

J Exp Clin Cancer Res. 2014 Nov 25;33:97. doi: 10.1186/s13046-014-0097-2.

14.

TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.

Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E, Chabaud S, Carrabin N, Chopin N, Bachelot T, Gillet G, Treilleux I, Rimokh R.

BMC Cancer. 2015 Jun 4;15:453. doi: 10.1186/s12885-015-1471-y.

15.

Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells.

Tagliabue E, Castiglioni F, Ghirelli C, Modugno M, Asnaghi L, Somenzi G, Melani C, Ménard S.

J Biol Chem. 2000 Feb 25;275(8):5388-94.

16.

Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer.

Labovsky V, Martinez LM, Calcagno ML, Davies KM, García-Rivello H, Wernicke A, Feldman L, Giorello MB, Matas A, Borzone FR, Howard SC, Chasseing NA.

Tumour Biol. 2016 Oct;37(10):13377-13384. Epub 2016 Jul 27.

PMID:
27460086
17.

Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.

Zhang Z, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Iwase H.

Clin Cancer Res. 2006 Nov 1;12(21):6410-4.

18.

Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis.

Liu F, Yang M, Li Z, Guo X, Lin Y, Lang R, Shen B, Pringle G, Zhang X, Fu L.

Breast Cancer Res Treat. 2015 Jun;151(2):443-51. doi: 10.1007/s10549-015-3413-4. Epub 2015 May 8.

PMID:
25953688
19.

Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.

Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM.

Clin Cancer Res. 2004 Nov 15;10(22):7621-8.

20.

[Relationship between SLP-2 expression and prognosis in laryngeal squamous cell carcinoma and mammary invasive carcinoma].

Cao WF, Zhang LY, Zhang B, Liu MB, Liu ZH, Sun BC.

Zhonghua Bing Li Xue Za Zhi. 2010 May;39(5):332-7. Chinese.

PMID:
20654157

Supplemental Content

Support Center